You know Hims, right? It’s the next-gen telehealth startup famous for taking the eye contact out of erectile dysfunction treatment. Of course, bedroom pills aren’t all Hims peddles. The Uberized men’s

Oral semaglutide, already approved for type 2 diabetes, led to a reduction in CV events in patients with established atherosclerotic disease, CKD, or both. Medscape Medical News

Semaglutide, a glucagon-like peptide 1 (GLP-1) agonist, significantly improved maximal walking distance in people with symptomatic peripheral artery disease (PAD) and Type 2 diabetes in the first-of-its kind trial to

The GLP-1 agonist has shown convincing benefits in yet another population, patients with peripheral arterial disease, in a practice-changing trial, according to experts. Medscape Medical News

New research shows GLP1-RA medications do not increase thyroid cancer risk, reassuring users and clinicians. A new study, published in the peer-reviewed journal Thyroid, the official journal of the American

A MOTHER has revealed that she has lost 10 and a half stone after using Mounjaro.  Becca Banks, a mum-of-one from the UK, confirmed that she once topped the scales

A large majority of older Americans feel that health insurance – including Medicare – should cover anti-obesity medications, according to a new University of Michigan study. And more than half

We recently published a list of Was Jim Cramer’s Call Right on These 10 Stocks? In this article, we are going to take a look at where Conagra Brands, Inc.

Novo Nordisk’s diabetes pill slashes risk of cardiovascular complications by 14% after four years  CNBC Semaglutide, or Ozempic, reduces symptoms of feared diabetes’ complication, study finds  The Globe and Mail Ozempic® (once-weekly

(Note: Thank you for supporting businesses like the one presenting a sponsored message below and working with them through the links below which benefits Gateway Pundit. We appreciate your support!)

A MOTHER has revealed that she lost over eight stone after using fat jabs for two years. Bridget claimed that everyone said she would regret using the weight loss injections,

We came across a bullish thesis on Viemed Healthcare, Inc. (VMD) on Substack by Petty Cash. In this article, we will summarize the bulls’ thesis on VMD. Viemed Healthcare, Inc. (VMD)’s share

Understanding the role of the brain in hedonic eating—the act of eating for pleasure rather than for physiological need—has been a popular endeavor. Researchers at the University of California, San

Lexicon Pharmaceuticals’ pursuit of the last word in obesity candidates has attracted Novo Nordisk. The Danish drugmaker is betting $75 million in upfront and near-term milestone payments to secure global

Patients with diabetes who take semaglutide are at increased risk for NAION compared with patients who do not use GLP-1 RAs to control their blood sugar, a new study finds.

Abstract Aims Type 1 diabetes mellitus (T1DM) is an autoimmune disease characterized by β-cell damage and absolute insulin deficiency. We consider combining immune intervention and β-cell replacement by biological scaffold

Summary Lymphedema is an important, and often underdiagnosed complication of obesity and is likely due to acquired defects in the lymphatic vasculature. Study of diet-induced obesity animal models have indicated

The partnership will give customers easy access to GLP-1 class drugs and other anti-obesity medications.  

Sen. Jim Banks (R-Ind.) wants the Food and Drug Administration to look into foreign-made active pharmaceutical ingredients he says are being included online weight loss drugs. In a letter to

Regaining weight after discontinuing GLP-1s is common, but ongoing coaching can help support patients to maintain their weight loss. Medscape Diabetes & Endocrinology

(MedPage Today) — CHICAGO — Coming this weekend, the American College of Cardiology (ACC) annual conference will feature research exploring new frontiers for GLP-1 drugs in cardiovascular medicine, and foundational

Viking Therapeutics VKTX announced that it has completed enrolling study participants in the phase II VENTURE-Oral Dosing study, which is evaluating the safety and efficacy of the oral formulation of

Over the last couple of years, the pharmaceutical sector has captivated investors thanks in large part to novel medications used to treat chronic weight management and diabetes. While you may

Many pharmaceutical companies and laboratories have been working for months to replicate the success of drugs such as Ozempic, Wegovy, and Zepbound. These medications are based on compounds originally developed

The obesity market is driving pharma’s return on investment (ROI) upward, with the projected return rising to 5.9% overall in 2024, but only reaching 3.8% if GLP-1 assets are excluded.

I’ve been meaning to write about this paper, although it’s not exactly medicinal chemistry (!) But it is a really novel – and rather daring – approach to cancer treatment,

A WOMAN has revealed the bizarre side effect of taking fat loss injections. Amy Kane lost 11 stone with the weight loss drug and is thrilled with the results. @amyinhalfAmy

What You Should Know:  – FuturHealth, a provider of personalized weight-loss solutions partners with Affirm, the payment network that empowers consumers and helps merchants drive growth.  – The collaboration will

What You Should Know:  – The pharmaceutical research and development (R&D) sector is experiencing a significant upswing, with projected returns on investment climbing to 5.9% in 2024, according to a

A recent study published in Nature Medicine may provide valuable insights into the previously unreported benefits and risks of glucagon-like peptide-1 (GLP-1) receptor agonist use on a set of 175

In the UK more than 3 in every 1000 people are taking glucagon-like peptide-1 (GLP-1) agonist drugs, says Kevin McCarroll, consultant physician and geriatrician at St James Hospital, Dublin.1 Depending

Related Stocks: NAS:AFRM,

With GLP-1 drugs like Ozempic all the rage, ChipMonk Baking has created a cookie it says works a bit the same way.

GLP-1s are driving traditional drug spending in the U.S. to unprecedented levels, which now outpaces specialty drug spending for the first time, according to a March 25 report from Evernorth.

Novo Nordisk said on Monday all eligible cash-paying customers in the United States can buy its weight-loss drug Wegovy at a discounted price of $499 per month at their… Reuters

Tirzepatide, a dual GIP/GLP-1 receptor agonist for diabetes, suppresses colorectal cancer growth by targeting glucose metabolism. It inhibits cancer cell proliferation, promotes apoptosis, and induces tumor regression. It reduces glucose

Patients with diabetes or obesity receiving GLP-1 RAs are unlikely to experience an increase in the already low rates of suicide-related adverse events in clinical trials. Medscape Medical News

It was only a matter of time until the GLP-1 receptor agonist drugs like Ozempic and Wegovy were superseded, and now it looks like we’ll have the next generation of

Amy Schumer is keeping people updated on her health. The 43-year-old comedian informed fans about her experience with taking an alternative weight loss drug called Mounjaro, after she couldn’t handle

Building upon its already impressive obesity drug portfolio, Novo Nordisk A/S has licensed a triple agonist of the receptors for GLP-1, GIP and glucagon from United Biotechnology Co. Ltd. China-based

With a FDA deadline set for March 26 to stop compounding versions of Zepbound, followed by restrictions on compounded Ozempic and Wegovy set for later this spring, the agency is

Learn how chemists have invented a new technology to solve the shortage of GLP-1 medications by improving drug delivery.

Huel Black Edition protein I’ve been loving Huel’s Ready-To-Drinks, but that’s only half of what the Black Edition collection has to offer. Maybe you’re more of a scoop-shake-drink kind of

Novo Nordisk is licensing rights to a United Biotechnology drug that sparks metabolic effects by binding to and activating receptors for GLP-1, GIP, and glucagon. Separately, the pharma giant said

A company is looking for a Clinical Care Advocate to support patients by addressing inquiries and ensuring a seamless patient experience. Key Responsibilities Serve as the primary point of contact

The candidate at the center of the deal, dubbed UBT251, is a triple agonist for glucagon-like peptide-1 (GLP-1), gastric inhibitory polypeptide (GIP) and glucagon.

Good morning, everyone, and welcome to another working week. We hope the weekend respite was relaxing and invigorating, because that oh-so-familiar routine of meetings, deadlines, and messages has returned. But

Novo Nordisk pays $200M upfront for China-based biotech’s triple-G obesity shot  Endpoints News Novo Signs $2 Billion Deal With United Labs for Obesity Drug  Bloomberg The United Laboratories and Novo Nordisk announce

Making America healthy again, it seems, starts with a double cheeseburger and fries. Earlier this month, Health Secretary Robert F. Kennedy Jr. visited a Steak ’n Shake in Florida and

LONDON–(BUSINESS WIRE)–Closed Loop Medicine Ltd., a leader in AI-enabled precision medicines, today announced the expansion of its US patent portfolio. Strengthening its cardiometabolic treatment portfolio, the Company now has patents

Butyrate, a short-chain fatty acid (SCFA) produced in your colon through the bacterial fermentation of dietary fiber, is a metabolite byproduct that nourishes your colonocytes (i.e., the cells lining your

The problem with Ozempic is that it works too well for obesity and weight loss. Imagine losing weight simply because you’re not hungry. Imagine suddenly disliking the taste of your